Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Fondation Plan Alzheimer | GE Healthcare | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Fondation Plan Alzheimer | GE Healthcare | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Florbetapir Calibration to the Centiloid Scale
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Feasibility of Florbetapir Quantitation in Europe
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2013
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Florbetapir (18F) in Japanese Healthy Volunteers
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Alzheimer's Drug Discovery Foundation | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Brain Beta-Amyloid on Postoperative Cognition
Details : Florbetapir F 18 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Alzheimer's Drug Discovery Foundation | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of PET Scan Timing Relative to AV-45 Injection Time
Details : Florbetapir F 18 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable